Hosted on MSN10mon
Ocugen says EU backs a U.S. trial for gene therapyOcugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback